The biotechnology firm scheduled a live webcast for 8:30 AM Eastern Time to disclose findings from the study. The presentation serves as a critical milestone for the company as it seeks to capture a share of the $15 billion global anti-VEGF market, which remains the primary target for its retinal vascular disease portfolio.

Zenkuda, known chemically as tarcocimab tedromer, and the bispecific candidate KSI-501 represent the core of the company’s current clinical focus. While the DAYBREAK data will provide a clearer picture of their performance in treating wet AMD, Kodiak continues to advance other late-stage programs, including the KSI-101 candidate for macular edema secondary to inflammation. Following the presentation, an archived replay will be hosted on the company’s investor relations website for a limited period.